* HELLO *
AND WELCOME
A DEDICATED COMPANY, WITH SOLID CREDENTIALS & AND AN EXTENSIVE FOOTPRINT IN PHARMA
READ MOREOUR WORK
HEALTH
IS EVERYTHING
WE ARE PART OF THE SOLUTION WHEN IT COMES TO UNIVERSAL ACCESS TO GOOD QUALITY MEDS
NEWSSTORIES
PHARMA
MARKETS
WE UNDERSTAND HOW TO GET YOUR PRODUCTS TO MARKET EFFICIENTLY AND WITH EASE
LEARN MOREGALLERY

Our Services

Clinical Research Development

At Pharma Strategies, we ensure that our clients optimally balance time, risk and cost in order to maximize the potential of a product…. Read More

Innovation Management

It is our observation that Pharma’s innovation focus remains on products and business models, and as such, Pharma Strategies …. Read More

Product Development Strategy

At Pharma Strategies, we combine clinical and commercial insights to transform your product development. Read More

New Market Access

Everybody’s talking about market access. But far fewer appear able to define it. In the competitive world of pharmaceutical … Read More

Business Development

Developing your business – through partnering, acquisition, licensing – and expanding your portfolio: a big ask in tough … Read More

Marketing & Education

Pharma Strategies is heavily involved in the provision of Marketing Excellence and Continuous Medical Education Read More

Why us?

We have the tools

We have all the tools necessary to execute complex tasks so that you dont have to!

Certified Experience

We are certfied industry leaders with an established footprint spanning many years.

Industry Experience

Our collective extensive experience and knowledge is over 30 years strong.

Smart Partnerships

We believe in smart partnerships. Therefore, our solutions are distinguished, tried, and tested.

Stakeholder Relationships

Our work spans across both the public and private sectors alike. We understand the dynamics of each.

Great Support

Our team is brilliant! We are here for the long haul & value each relationship, old and new.

Some of our Products

Latest News

Novartis Phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair® Breezhaler® (QVM149) versus a free combination of two existing inhaled treatments in uncontrolled asthma

Once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) met primary endpoint, demonstrating non-inferiority to a free combination of twice-daily Sal/Flu plus once-daily tiotropium (Tio), in improving quality of life in people with uncontrolled asthma1.Am…

Novartis PREVENT data show Cosentyx® helps patients realize early and lasting relief in axial spondyloarthritis

Phase III PREVENT data show Cosentyx® 150 mg provided significant and sustained improvement in signs and symptoms of non-radiographic axial spondyloarthritis (nr-axSpA) up to Week 521 nr-axSpA is the fourth EU indication for Cosentyx, providing patient…

© Copyright - Pharma Strategies | Zimbabwe